Steven P. Treon
史蒂文·特雷昂
MD, PhD, MA
Director, Bing Center for Waldenström's Macroglobulinemia瓦尔登斯特伦巨球蛋白血症宾氏中心主任
👥Biography 个人简介
Professor Steven Treon is the world's foremost authority on Waldenström macroglobulinemia (WM). His laboratory discovered the MYD88 L265P somatic mutation present in over 90% of WM patients, fundamentally transforming the diagnosis and treatment of this disease and establishing it as a genetically distinct entity. He pioneered the use of ibrutinib in WM and contributed to the ASPEN trial that led to the FDA approval of zanubrutinib for WM in 2021. Treon directs the only dedicated WM research center in the world and has organized the International Workshops on WM for over two decades.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Discovery of MYD88 L265P in Waldenström Macroglobulinemia
Led the whole genome sequencing study that identified the MYD88 L265P oncogenic mutation in >90% of WM patients. This discovery enabled molecular diagnosis, informed BTK inhibitor selection, and changed the understanding of WM as a molecularly distinct lymphoma subtype.
Ibrutinib Approval in WM
Principal investigator for the INNOVATE trial establishing ibrutinib plus rituximab as a standard of care in both treatment-naïve and relapsed/refractory WM, leading to FDA approval and transforming WM from an incurable to a chronically manageable disease.
Zanubrutinib in WM — ASPEN Trial
Led the ASPEN phase III trial comparing zanubrutinib versus ibrutinib in WM, demonstrating superior complete and very good partial response rates for zanubrutinib with reduced atrial fibrillation risk, informing FDA approval of zanubrutinib for WM in 2021.
Representative Works 代表性著作
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia
New England Journal of Medicine (2012)
Landmark discovery paper identifying the MYD88 L265P mutation in the vast majority of WM cases, cited over 2,000 times.
Zanubrutinib versus ibrutinib in symptomatic Waldenström macroglobulinemia: a randomized phase 3 trial (ASPEN)
Journal of Clinical Oncology (2021)
Head-to-head phase III trial demonstrating zanubrutinib superiority in WM treatment response with improved tolerability.
Ibrutinib plus rituximab in previously untreated and previously treated Waldenström's macroglobulinemia (iNNOVATE)
The Lancet Oncology (2018)
Phase III trial establishing ibrutinib-rituximab as a key standard of care for symptomatic WM.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-20 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 史蒂文·特雷昂 的研究动态
Follow Steven P. Treon's research updates
留下邮箱，当我们发布与 Steven P. Treon（Dana-Farber Cancer Institute, Harvard Medical School）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment